- Home
- NIVF vs SLXN Comparison
NIVF vs SLXN Comparison
Compare NIVF & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- SLXN
- Stock Information
- Founded
- NIVF 2011
- SLXN 2008
- Country
- NIVF Hong Kong
- SLXN Israel
- Employees
- NIVF N/A
- SLXN N/A
- Industry
- NIVF
- SLXN
- Sector
- NIVF
- SLXN
- Exchange
- NIVF NYSE
- SLXN NYSE
- Market Cap
- NIVF 3.9M
- SLXN 4.3M
- IPO Year
- NIVF N/A
- SLXN N/A
- Fundamental
- Price
- NIVF $2.11
- SLXN $0.84
- Analyst Decision
- NIVF
- SLXN Strong Buy
- Analyst Count
- NIVF 0
- SLXN 1
- Target Price
- NIVF N/A
- SLXN $9.00
- AVG Volume (30 Days)
- NIVF 2.6M
- SLXN 31.1M
- Earning Date
- NIVF 02-16-2025
- SLXN 03-04-2025
- Dividend Yield
- NIVF N/A
- SLXN N/A
- EPS Growth
- NIVF N/A
- SLXN N/A
- EPS
- NIVF N/A
- SLXN N/A
- Revenue
- NIVF $5,679,218.00
- SLXN N/A
- Revenue This Year
- NIVF N/A
- SLXN N/A
- Revenue Next Year
- NIVF N/A
- SLXN N/A
- P/E Ratio
- NIVF N/A
- SLXN N/A
- Revenue Growth
- NIVF N/A
- SLXN N/A
- 52 Week Low
- NIVF $0.11
- SLXN $0.21
- 52 Week High
- NIVF $17.24
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- NIVF 76.40
- SLXN N/A
- Support Level
- NIVF $1.85
- SLXN N/A
- Resistance Level
- NIVF $2.89
- SLXN N/A
- Average True Range (ATR)
- NIVF 0.30
- SLXN 0.00
- MACD
- NIVF 0.18
- SLXN 0.00
- Stochastic Oscillator
- NIVF 72.03
- SLXN 0.00
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.